As the year comes to a close, we revisit some of this year’s top content on kidney cancer.
There’s been an abundance of news surrounding kidney cancer over the past year. In light of all that has been discovered, Urology Times® is counting down the top pieces of content on kidney cancer in 2022.
Peter A. Humphrey, MD, PhD, provided an overview of important takeaways in bladder and kidney cancer that were discussed at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies. Watch now.
The combination of pembrolizumab (Keytruda) and lenvatinib (Lenvima) showed encouraging antitumor activity as a frontline treatment for patients with non–clear cell renal cell carcinoma, according to preliminary findings from the phase 2 KEYNOTE-B61 trial. Read more.
Kevin Hakimi discussed the background and results of the study, “Interim analysis of PADRES (prior axitinib as a determinant of outcome of renal surgery) clinical trial,” which he presented at the 2022 AUA Annual Meeting. Watch now.
Stereotactic ablative radiotherapy (SAbR) demonstrated meaningful longitudinal disease control in patients with systemic therapy–naïve oligometastatic renal cell carcinoma (RCC), according to findings from a phase 2 study published in European Urology Oncology. Read more.
Laura Bukavina, MD, MPH, and Sarah P. Psutka, MD, MS, discussed the questions raised by the European Urology study, “Epidemiology of Renal Cell Carcinoma: 2022 Update.” Watch now.
Combination therapy with the novel TKI sitravatinib and the anti–PD-1 immune checkpoint inhibitor nivolumab (Opidvo) showed promising efficacy and safety in patients with clear cell renal cell carcinoma and progression after antiangiogenic therapy, according to findings from a phase 1/2 trial. Read more.
The approval was based on the phase 3 KEYNOTE-564 trial, which showed that at a median follow-up of approximately 24 months, the median disease-free survival was not reached with either adjuvant pembrolizumab or placebo as per investigator assessment. Read more.
Michael Staehler, MD, discussed early results with 68GA-EMP-100 PET, a novel agent for imaging c-MET expression in renal cell carcinoma. The data were presented at the 2022 AUA annual meeting. Watch now.
After FDA approval of pembrolizumab last year, many researchers and clinicians were interested to find out the long-term efficacy of this treatment. Read more.
In this video, Janet Kukreja, MD, discussed abstracts on urothelial carcinoma, renal cell carcinoma, and muscle-invasive bladder cancer that were presented at the 2022 Genitourinary Cancers Symposium. Watch now.